Fundamental Analysis of Immuneering Corp - Growth / Value Index
IMRX - Valuation Highlights
Valuation Analysis
Price to Book Ratio is 0.521 indicating that it is undervalued.
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.298 | -858.54 | -105255.83 % | |
| Price to Book | 0.192 | 0.489 | 30.61 % | 0.0006 |
| Price to Sales | 0 | 97428198 | 75017953 % | |
| Enterprise Value to EBITDA Multiple | 1.38 | 291.01 | 47173.69 % |
IMRX - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -64.50 | -0.057 | 99.88 % | -18.17 |
| Return On Asset | -58.79 | -0.050 | 99.88 % | -16.26 |
| Net Profit Margin | 0 | -11348063.96 | -71104.46 % | 0 |
| Operating Profit Margin | 0 | -12328880.66 | -75417.89 % | 0 |
| EBITDA Margin | 0 | -11159331.87 | -69921.31 % | 0 |
Highlights
| Market Cap | 46259.30 K |
| Enterprise Value | -59059.45 M |
| Price/Book TTM | 0.192 |
| Outstanding Share | 29653.40 K |
| Float/ Outstanding Share | 57.34% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | -2.23 |
| Sloan Ratio | -0.0000 |
| Peter Lynch Fair Value | 0 |
IMRX - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 71104.46%
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 34.14
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Companies' sales dropped by 99.86 % from last year
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | NA | 99.86 % | 100.00 % |
| Gross Profit | 94038.00 K | 99.71 % | 100.00 % |
| EBITDA | -42772.06 M | 0.519 % | 102164 % |
| Net Profit | -38445.43 M | 2.22 % | 94757.54 % |
| EPS | -5.24 | 99.91 % | NA |
IMRX - Stability Highlights
Stability Analysis
Cash ratio of 10.92
Altman Z Score of -2.23 suggest high risk
Company's debt has increased with decreasing revenue.
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0033 | -3.90 % | 0.0038 |
| Cash Ratio | 10.92 | -16.66 % | |
| Quick Ratio | 0 | 0 % | 14.38 |
| Shareholders Equity | 88.29 | -1.65 % | |
| Debt to EBITDA | -5.91 | -78732.68 % |
Historical Valuation Ratios of Immuneering Corp
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Immuneering Corp
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Immuneering Corp
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Immuneering Corp
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)